AbCellera Biologics Inc vs Centrus Energy Corp — how do they compare? AbCellera Biologics Inc trades at $9.19 (market cap $2.99B), while Centrus Energy Corp trades at $195.1 (market cap $3.77B). The key difference: Centrus Energy Corp is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | LEU | |
|---|---|---|
Market Cap | $2.99B | $3.77B |
Sector | Health | Energy |
52-Week High | $9.76 | $436.00 |
52-Week Low | $2.78 | $146.61 |
Enterprise Value | $2.58B | $3.08B |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →